Cyclacel Pharmaceuticals (CYCC) Given a $7.00 Price Target at HC Wainwright

Cyclacel Pharmaceuticals (NASDAQ:CYCC) received a $7.00 price objective from investment analysts at HC Wainwright in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 343.04% from the stock’s previous close.

CYCC has been the topic of a number of other reports. Zacks Investment Research raised shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. ValuEngine raised shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Cyclacel Pharmaceuticals traded up $0.02, reaching $1.58, on Friday, according to 13,571 shares of the company traded hands, compared to its average volume of 39,932. Cyclacel Pharmaceuticals has a 52-week low of $1.28 and a 52-week high of $2.27.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.04). equities research analysts predict that Cyclacel Pharmaceuticals will post -0.43 EPS for the current year.

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 70,310 shares of the biotechnology company’s stock, valued at approximately $122,000. Two Sigma Investments LP owned approximately 0.59% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 4.67% of the stock is owned by institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

See Also: Find a Trading Strategy That Works

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply